Janssen Research & Development
1400 McKean Road
About Janssen Research & DevelopmentAt Janssen Research & Development, LLC, we are united and energized by one mission – to discover and develop innovative medicines that ease patients' suffering, and solve the most important unmet medical needs of our time.
As one of the Janssen Pharmaceutical Companies, our strategy is to identify the biggest unmet medical needs and match them with the best science, internal or external, to find solutions for patients worldwide. We leverage our world-class discovery and development expertise, and operational excellence, to bring innovative, effective treatments in five therapeutic areas:
• cardiovascular and metabolism, • immunology, • infectious diseases and vaccines, • neuroscience, and • oncology.
We think of the world as our laboratory and we look for innovation wherever it exists. This drives our relentless search for the best science, and our pursuit of collaborations and partnerships.
We believe there are no limits to what science can do. And we never lose sight of those who rely most on our discoveries.
Janssen Labs is part of Johnson & Johnson’s external research and development engine and provides a capital-efficient, resource-rich environment where independent emerging companies can progress their research. The 30,000 square foot flagship facility opened in early 2012 in San Diego at Janssen’s West Coast Research Center and currently hosts 30 emerging life science companies. Janssen Labs offers singular bench tops, modular wet lab units and office space on a short-term basis, allowing companies to pay only for the space they need, with an option to quickly expand when they have the resources to do so. Janssen Labs is an open innovation model, and the agreement for space does not grant Janssen any stake in the companies, nor will the companies have a guaranteed future affiliation with Janssen; but the models is designed to initiate a dialogue early and foster long term relationships with innovators in healthcare.
52 articles with Janssen Research & Development
Although vaccines and effective therapeutics are powerful tools in preventing and treating COVID-19, we’re not done battling the disease just yet. For those stories and more, read on.
AI can enable the analysis of massive databases, accelerate research and development, save costs and promote effective decision making.
Studies are also continuing on the value and efficacy of booster shots, particularly against the Delta variant. Read on for more information.
It was based on data from the APOLLO trial showing the drug significantly decreased the risk of progression or death by 37% compared to dexamethasone alone.
Janssen presented the Phase III Glow study for the elderly with CLL or SLL and the overall survival results from the Phase III MAIA study for patients with NDMM.
Shares of Protagonist Therapeutics climbed nearly 4% in premarket trading after the company announced its lead drug candidate rusfertide snagged Breakthrough Therapy Designation from the U.S. FDA.
IQVIA Collaborating with Janssen Research & Development on Their Investigational COVID-19 Vaccine Trials
IQVIA™ (NYSE: IQV) announces that since September 2020 it has been collaborating with Janssen Research & Development, LLC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, on the Phase 3 COVID-19 vaccine clinical trials. The studies leverage IQVIA’s suite of decentralized trial solutions that support both on-site and remote study delivery through a mix of tel
Leading Biopharmaceutical Companies Select Invitae to Develop Standardized Panel to Detect Molecular Residual Disease (MRD) in Patients with Acute Myeloid Leukemia (AML)
-- Project aims to standardize MRD data generation, assessment and accelerate AML clinical trial programs bringing novel therapies to patients in need faster --
DGAP-News: MorphoSys' Licensee Announces Approval by the European Commission for Tremfya(R) (guselkumab) for Treatment of Adults with Active Psoriatic Arthritis (PsA)
MorphoSys AG announced that its licensee Janssen Research & Development, LLC. reported the European Commission's approval for the use of Tremfya in the treatment of adult patients with active psoriatic arthritis who have had an inadequate response or who have been intolerant to a prior disease-modifying antirheumatic drug therapy.
Tempus Announces Strategic Collaboration With Janssen Applying Data Science to Enhance Therapeutic Development
Tempus, a leader in artificial intelligence (AI) and precision medicine, today announced a strategic collaboration with Janssen Research & Development, LLC (Janssen), in which Tempus will work closely with Janssen data scientists and oncologists focused on oncology clinical development programs. The collaboration is part of a multi-year data agreement, which is facilitating predictive AI/machine learning projects, as well as
Research alliance will leverage advanced data analytics and genomic testing to improve recruitment of patients in oncology clinical trials
GeneCentric Therapeutics Enters into Research Collaboration with Janssen on Genomic Drug Response Biomarkers for Non-Muscle Invasive Bladder Cancer
GeneCentric Therapeutics today announced it has entered into a research collaboration with Janssen Research & Development, LLC (Janssen) around RNA-based drug response biomarkers for non-muscle invasive bladder cancer (NMIBC). The research will involve the application of GeneCentric’s advanced RNA-based molecular profiling platform to elucidate poten
The Industrial Macromolecular Crystallography Association, an association of pharmaceutical companies that leverages the power of high-energy X-rays to accelerate structural biology research for drug discovery, announced that Janssen Research & Development, LLC has joined IMCA.
IMMUNOPRECISE ANTIBODIES LTD., a global leader in therapeutic antibody discovery and development, announced that it, through its subsidiary Talem Therapeutics, has entered into a research license agreement with Janssen Research & Development, LLC, providing Janssen exclusive access to a panel of novel, monoclonal antibodies against an undisclosed target.
An oral, gut-restricted IL-23 receptor antagonist peptide is successfully nominated as a second-generation development candidate, advancing the collaboration and triggering a $5M milestone payment
Target Discovery and Therapeutic Validation Collaboration is Resonant’s First Announced Deal
MorphoSys's Licensee Janssen Submits Biologics License Application to U.S. FDA of Tremfya(R) (Guselkumab) for Treatment of Adults with Active Psoriatic Arthritis
MorphoSys AG announced that its licensee Janssen Research & Development, LLC issued a press release to report the submission of a supplemental Biologics License Application to the U.S. Food and Drug Administration seeking approval of Tremfya for the treatment of adult patients with active psoriatic arthritis.
ADS to provide expertise and capabilities in antibody drug discovery
Resolution Advancing Development of Cell-Free DNA Companion Diagnostic for Prostate Cancer through Collaboration with Janssen
Liquid biopsy assay with recent Breakthrough Device Designation from FDA is being used to screen patients with prostate cancer for HRD mutations and deletions as part of phase II and III clinical studies
Companies to share proteomic and clinical data to drive new drug discovery and development, and precision health management